Clinical trials: in Singapore
Obesity & Overweight
Effects of Protein Supplementation on 4 Weeks of Alternate-day Fasting on Fasting Blood Glucose, Resting Blood Pressure, and Body Composition in Young Men
The objectives of this study are to examine the effects of protein supplementation on 4 weeks of alternate-day fasting (ADF) on fasting blood glucose, resting blood pressure, and body composition in young Asian men with unhealthy…
- Trial name
- NCT07241689
- Testing
- protein supplement, No supplementation
- Where
- Singapore
- Volunteers
- 26 people
- Sponsor
- Nanyang Technological University
Hereditary Angioedema, Hereditary Angioedema Type I
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand…
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
- Trial name
- RAPIDe-3 (NCT06343779)
- Where
- 76 sites in United States, Argentina and 27 more
- Volunteers
- 134 people
- Sponsor
- Pharvaris Netherlands B.V.
Root Canal Obturation
Root Canal Treatment With TotalFill® Bioceramic Sealer and AH Plus® Sealer
The study design is a double blinded randomized controlled trial and 170 subjects (teeth) , 85 in each of the 2 groups, will be enrolled from the patients at the NUH dental centre endodontic unit.
- Trial name
- NCT03732170
- Testing
- TotalFill® Bioceramic sealer, AH plus® sealer
- Where
- Singapore
- Volunteers
- 170 people
- Sponsor
- National University Hospital, Singapore
Non-alcoholic Steatohepatitis
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
- Trial name
- NCT05016882
- Testing
- NNC0194 0499 50 mg/mL, Semaglutide 3 mg/mL, NNC0174 0833 10 mg/mL
- Where
- 255 sites in United States, Australia and 22 more
- Volunteers
- 698 people
- Sponsor
- Novo Nordisk A/S
Cataract, Surgery
Patient-preferred Aromatherapy Versus Placebo For Reducing Preoperative Anxiety In Patients Undergoing Eye Surgery
This study looks at whether aromatherapy (scent chosen by the patient), is better than routine care, at reducing preoperative anxiety before eye surgery.
- Conditions
- Cataract, Surgery, Vitrectomy, Aromatherapy
- Trial name
- RELAAC (NCT07237061)
- Testing
- Aromatherapy
- Where
- Singapore
- Volunteers
- 64 people
- Sponsor
- National University Hospital, Singapore
Obesity, Childhood, Cognition
NiPPeR Randomised Trial - Child Follow Up Study
There is an increasing focus on the need to optimise nutrition, lifestyle and metabolism of parents before and during pregnancy and of the infant after birth, but as yet there is limited understanding of the specific influences…
- Conditions
- Obesity, Childhood, Cognition, Neurobehavioral Manifestations, Metabolic Disturbance
- Trial name
- NiPPeR Child (NCT05934422)
- Testing
- Intervention (Study Nutritional Drink), Control (Standard Nutritional Drink)
- Where
- 3 sites in New Zealand, Singapore and 1 more
- Volunteers
- 461 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants.
- Trial name
- NCT06916091
- Testing
- Eloralintide
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
NSCLC, Non Small Cell Lung Cancer
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the…
- Trial name
- NCT01221077
- Testing
- OSI-906, Erlotinib
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 88 people
- Sponsor
- Astellas Pharma Inc
Colorectal Cancer
Window of Opportunity Study in Colorectal Cancer
This is a window of opportunity translational study investigating the use of pre-operative pembrolizumab and chemotherapy or chemoradiotherapy in non-metastatic colorectal cancer.
- Trial name
- NCT03984578
- Testing
- CAPEOX, Pembrolizumab, Capecitabine/ 5-FU
- Where
- 3 sites in Singapore
- Volunteers
- 33 people
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma Resectable
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
Clinical outcomes after surgical resection in HCC is a continuum and is clearly related to tumor burden but needs better definition.
- Trial name
- NCT06294808
- Where
- 2 sites in Singapore
- Volunteers
- 1,043 people
- Sponsor
- National Cancer Centre, Singapore
Polypoidal Choroidal Vasculopathy
Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
To determine long-term outcomes, recurrence rates, and treatment needs in Polypoidal Choroidal Vasculopathy (PCV). Specifically, to describe the long-term outcomes, recurrence rates and treatment patterns PCV patients 5 years…
- Trial name
- NCT03929731
- Testing
- Indocyanine Green Angiography
- Where
- 3 sites in Singapore
- Volunteers
- 72 people
- Sponsor
- Singapore National Eye Centre
Advanced Cancer
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
- Trial name
- CheckMate 577 (NCT02743494)
- Testing
- Nivolumab
- Where
- 204 sites in United States, Argentina and 29 more
- Volunteers
- 794 people
- Sponsor
- Bristol-Myers Squibb
Polypoidal Choroidal Vasculopathy
Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT03941587
- Testing
- Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
- Where
- 2 sites in Singapore
- Volunteers
- 60 people
- Sponsor
- Singapore National Eye Centre
Advanced Solid Tumors, Triple Negative Breast Cancer
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
The purpose of this "first-in-human" study of FAZ053 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of FAZ053 administered Intravenously (i.v.)as a single agent or…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
- Trial name
- NCT02936102
- Testing
- FAZ053, PDR001
- Where
- 12 sites in United States, Canada and 7 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Neoplasms
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
- Trial name
- IMpassion132 (NCT03371017)
- Testing
- Atezolizumab, Gemcitabine, Capecitabine
- Where
- 124 sites in United States, Argentina and 26 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
- Trial name
- ADjoin (NCT04392154)
- Testing
- Lebrikizumab
- Where
- 321 sites in United States, Australia and 14 more
- Volunteers
- 1,153 people
- Sponsor
- Eli Lilly and Company
Hidradenitis Suppurativa
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS.
- Trial name
- NCT05819398
- Testing
- Spesolimab i.v., Spesolimab s.c.
- Where
- 162 sites in United States, Argentina and 33 more
- Volunteers
- 209 people
- Sponsor
- Boehringer Ingelheim
Clinical High Risk, Psychosis
AMP SCZ® Observational Study: PREDICT-DPACC
The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that…
- Conditions
- Clinical High Risk, Psychosis, Remission, Conversion
- Trial name
- AMP SCZ (NCT05905003)
- Where
- 42 sites in United States, Australia and 12 more
- Volunteers
- 2,617 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Influenza Vaccination
Immunogenicity Trial of 3 Influenza Vaccines
This study is a prospective randomised trial of 3 influenza vaccine formulations with different manufacturing processes: 1) egg-grown (QIV-E); 2) cell-grown (QIV-C); and 3) recombinant protein (QIV-R).
- Trial name
- NCT05479370
- Testing
- Flublok Quadrivalent vaccine, Fluarix Quadrivalent vaccine, Flucelvax Quadrivalent vaccine
- Where
- Singapore
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Septic Shock
Stress Hydrocortisone In Pediatric Septic Shock
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and…
- Trial name
- SHIPSS (NCT03401398)
- Testing
- Hydrocortisone, sodium succinate, Normal saline
- Where
- 44 sites in United States, Brazil and 8 more
- Volunteers
- 500 people
- Sponsor
- Jerry Zimmerman
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.